ERBB2 and breast cancer: HER2DX was further validated for its prognostic role in an independent evaluation cohort of patients with early-stage HER2+ BC enrolled in four other clinical studies (conducted in either the adjuvant or neoadjuvant setting), thus emerging as a promising tool potentially capable of optimizing the prognostic stratification of patients with early HER2 BC [37].